{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:04:17Z","timestamp":1790193857793,"version":"4.1.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82141104"],"award-info":[{"award-number":["82141104"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction or hypothesis<\/jats:title>\n                  <jats:p>The SANET-ep study confirmed that patients with non-pancreatic NET could benefit from surufatinib treatment compared with placebo. However, there is a lack of sufficient retrospective data on surufatinib\u2019s efficacy in treating thymic neuroendocrine tumors (TNETs). This study aimed to evaluate the efficacy and safety of surufatinib in well-differentiated TNETs by conducting a single center retrospective analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a retrospective study at Fudan University Shanghai Cancer Center, including 102 patients with TNETs. This study assessed the efficacy and safety of surufatinib in this population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Median progression-free survival was 10.0 months, ORR was 5.6%, and DCR was 83.1%. Surufatinib performed better in first-line treatment compared to secondary treatment in terms of ORR, DCR, and mPFS. The most common adverse events were diarrhea (15.7%), hypertension (19.1%), proteinuria (13.5%), and hypothyroidism (5.6%). About 33.3% of patients required dosage reduction from 300\u00a0mg\/day to 200\u00a0mg\/day (or 250\u00a0mg\/day) due to adverse events, which in most cases were mitigated or disappeared with dose reduction.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>For patients with advanced, progressive, well-differentiated TNETs, Surufatinib can be used as an option with a high mPFS and DCR. Moreover, the safety profile of surufatinib was found to be acceptable. These findings suggest that surufatinib could potentially serve as an innovative therapeutic option for this particular patient population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf072","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T17:25:06Z","timestamp":1743355506000},"source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of surufatinib in the treatment of thymic neuroendocrine tumors: a 102-case retrospective study."],"prefix":"10.1093","volume":"30","author":[{"given":"Xuebing","family":"Jia","sequence":"first","affiliation":[{"name":"Centre for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center , Shanghai 200032 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichen","family":"Sun","sequence":"additional","affiliation":[{"name":"Centre for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center , Shanghai 200032 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Fudan University Shanghai Cancer Center , Shanghai 200032 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Fudan University Shanghai Cancer Center , Shanghai 200032 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengzhen","family":"Chen","sequence":"additional","affiliation":[{"name":"Centre for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center , Shanghai 200032 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[{"name":"Centre for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center , Shanghai 200032 ,","place":["People\u2019s Republic of China"]},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai 200032 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3759-2997","authenticated-orcid":false,"given":"Yun","family":"Liang","sequence":"additional","affiliation":[{"name":"Centre for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center , Shanghai 200032 ,","place":["People\u2019s Republic of China"]},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai 200032 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"2025092116020593900_CIT0001","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1097\/SLA.0b013e3181dd4ec4","article-title":"Thymic neuroendocrine tumors: a SEER database analysis of 160 patients","volume":"251","author":"Gaur","year":"2010","journal-title":"Ann Surg."},{"key":"2025092116020593900_CIT0002","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.tem.2023.12.003","article-title":"A clinical perspective on ectopic Cushing\u2019s syndrome","volume":"35","author":"Ragnarsson","year":"2024","journal-title":"Trends Endocrinol Metab"},{"key":"2025092116020593900_CIT0003","doi-asserted-by":"publisher","first-page":"1183297","DOI":"10.3389\/fendo.2023.1183297","article-title":"Expressions of Cushing\u2019s syndrome in multiple endocrine neoplasia type 1","volume":"14","author":"Simonds","year":"2023","journal-title":"Front Endocrinol."},{"key":"2025092116020593900_CIT0004","doi-asserted-by":"publisher","first-page":"20406223211035288","DOI":"10.1177\/20406223211035288","article-title":"Multiple endocrine neoplasia 1: a broad overview","volume":"12","author":"Thompson","year":"2021","journal-title":"Ther Adv Chronic Dis"},{"key":"2025092116020593900_CIT0005","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s11154-021-09660-2","article-title":"Ectopic Cushing\u2019s syndrome due to thymic neuroendocrine tumours: a systematic review","volume":"22","author":"Guerrero-P\u00e9rez","year":"2021","journal-title":"Rev Endocr Metab Disord"},{"key":"2025092116020593900_CIT0006","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.annonc.2021.01.003","article-title":"Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(\u2606)","volume":"32","author":"Baudin","year":"2021","journal-title":"Ann Oncol"},{"key":"2025092116020593900_CIT0007","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-term efficacy, survival, and safety of [(177)Lu-DOTA(0),Tyr(3)]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors","volume":"23","author":"Brabander","year":"2017","journal-title":"Clin Cancer Res."},{"key":"2025092116020593900_CIT0008","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41574-020-00439-0","article-title":"Surufatinib - a novel oral agent for neuroendocrine tumours","volume":"17","author":"Koumarianou","year":"2021","journal-title":"Nat Rev Endocrinol."},{"key":"2025092116020593900_CIT0009","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1158\/1078-0432.CCR-18-2994","article-title":"Surufatinib in advanced well-differentiated neuroendocrine tumors: a multicenter, single-arm, open-label, phase Ib\/II trial","volume":"25","author":"Xu","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2025092116020593900_CIT0010","doi-asserted-by":"publisher","first-page":"42076","DOI":"10.18632\/oncotarget.14942","article-title":"Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study","volume":"8","author":"Xu","year":"2017","journal-title":"Oncotarget"},{"key":"2025092116020593900_CIT0011","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/S1470-2045(20)30493-9","article-title":"Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-P): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Xu","year":"2020","journal-title":"Lancet Oncol."},{"key":"2025092116020593900_CIT0012","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1001\/jama.2023.5444","article-title":"Diagnosis and management of pituitary adenomas: a review","volume":"329","author":"Tritos","year":"2023","journal-title":"JAMA."},{"key":"2025092116020593900_CIT0013","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1016\/j.clcc.2018.07.013","article-title":"ACTH-secreting neuroendocrine carcinoma of the cecum: case report and review of the literature","volume":"18","author":"Mokhtar","year":"2019","journal-title":"Clin Colorectal Cancer."},{"key":"2025092116020593900_CIT0014","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3322\/caac.21493","article-title":"Gastroenteropancreatic neuroendocrine tumors","volume":"68","author":"Cives","year":"2018","journal-title":"CA Cancer J Clin."},{"key":"2025092116020593900_CIT0015","doi-asserted-by":"publisher","first-page":"721","DOI":"10.2967\/jnumed.118.214882","article-title":"Medical management of gastroenteropancreatic neuroendocrine tumors: current strategies and future advances","volume":"60","author":"Mohamed","year":"2019","journal-title":"J Nucl Med"},{"key":"2025092116020593900_CIT0016","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"key":"2025092116020593900_CIT0017","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1093\/annonc\/mdv252","article-title":"Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)","volume":"26","author":"Grande","year":"2015","journal-title":"Ann Oncol"},{"key":"2025092116020593900_CIT0018","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/nejmoa2403991","article-title":"Phase 3 trial of cabozantinib to treat advanced neuroendocrine tumors","volume":"392","author":"Chan","year":"2024","journal-title":"N Engl J Med."},{"key":"2025092116020593900_CIT0019","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/s41571-024-00949-0","article-title":"CABINET presents cabozantinib as a new treatment option for NETs","volume":"21","author":"Killock","year":"2024","journal-title":"Nat Rev Clin Oncol."},{"key":"2025092116020593900_CIT0020","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s13023-022-02366-x","article-title":"Real-world clinicopathological features and outcome of thymic neuroendocrine tumors: a retrospective single-institution analysis","volume":"17","author":"Chen","year":"2022","journal-title":"Orphanet J Rare Dis."},{"key":"2025092116020593900_CIT0021","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41419-023-06211-2","article-title":"Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity","volume":"14","author":"Liu","year":"2023","journal-title":"Cell Death Dis"},{"key":"2025092116020593900_CIT0022","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1158\/1078-0432.CCR-18-2581","article-title":"The reciprocity between radiotherapy and cancer immunotherapy","volume":"25","author":"Wang","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2025092116020593900_CIT0023","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12885-022-09194-z","article-title":"Extracellular vesicles mediated proinflammatory macrophage phenotype induced by radiotherapy in cervical cancer","volume":"22","author":"Ren","year":"2022","journal-title":"BMC Cancer"},{"key":"2025092116020593900_CIT0024","doi-asserted-by":"publisher","first-page":"101366","DOI":"10.1016\/j.tranon.2022.101366","article-title":"Radiotherapy: brightness and darkness in the era of immunotherapy","volume":"19","author":"Zhai","year":"2022","journal-title":"Transl Oncol."},{"key":"2025092116020593900_CIT0025","doi-asserted-by":"publisher","first-page":"100453","DOI":"10.1016\/j.esmoop.2022.100453","article-title":"Treatment-related adverse events as predictive biomarkers of efficacy in patients with advanced neuroendocrine tumors treated with surufatinib: results from two phase III studies","volume":"7","author":"Li","year":"2022","journal-title":"ESMO Open"},{"key":"2025092116020593900_CIT0026","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00432-021-03898-8","article-title":"Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial","volume":"149","author":"Cao","year":"2023","journal-title":"J Cancer Res Clin Oncol."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/5\/oyaf072\/63370828\/oyaf072.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/5\/oyaf072\/63370828\/oyaf072.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T20:02:15Z","timestamp":1758484935000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf072\/8151385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf072","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,5]]},"article-number":"oyaf072"}}